Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Page 2

BlueSphere Bio brings in $45.6m
Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.
Biohaven brings Kleo into the fold
Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.
Immunocore impresses with $75m series C
The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.
Johnson & Johnson turns Paige to $100m
Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.
Atalanta attains series A
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.
Sana to seek $150m in IPO
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
SpyGlass observes $27.5m
The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.
Lexeo stacks up $85m
Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.
LifeMine Therapeutics lands $50m
LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.
Daily deal net: January 12, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

test reg